Literature DB >> 32392079

Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors.

Manuel Silva-Carmona1, Tiphanie P Vogel1, Sarah Marchal2, Myriam Guesmi3, Jean-Christophe Dubus4, Sylvie Leroy5, Alexandre Fabre6, Vincent Barlogis7, Lisa R Forbes1, Lisa Giovannini-Chami8.   

Abstract

Entities:  

Keywords:  ILD; JAK inhibitor; Jakinibs; STAT3; STAT3 GOF

Year:  2020        PMID： 32392079     DOI： 10.1164/rccm.201906-1204LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  8 in total

Review 1.  Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.

Authors:  Alesandra Florescu; Florin Liviu Gherghina; Anca Emanuela Mușetescu; Vlad Pădureanu; Anca Roșu; Mirela Marinela Florescu; Cristina Criveanu; Lucian-Mihai Florescu; Anca Bobircă
Journal:  Biomedicines       Date:  2022-06-09

2.  A Novel STAT3 Gain-of-Function Mutation in Fatal Infancy-Onset Interstitial Lung Disease.

Authors:  Mengyue Deng; Yue Li; Yulu Li; Xiaolan Mao; Han Ke; Weiling Liang; Xiaoguang Lei; Yu-Lung Lau; Huawei Mao
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

3.  Efficacy of tocilizumab therapy in a patient with severe pancytopenia associated with a STAT3 gain-of-function mutation.

Authors:  Wenjie Wang; Luyao Liu; Xiaoying Hui; Ying Wang; Wenjing Ying; Qinhua Zhou; Jia Hou; Mi Yang; Bijun Sun; Jinqiao Sun; Xiaochuan Wang
Journal:  BMC Immunol       Date:  2021-03-17       Impact factor: 3.615

Review 4.  Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease.

Authors:  Andrew Bush; Ian D Pavord
Journal:  Breathe (Sheff)       Date:  2021-09

Review 5.  Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.

Authors:  Rongxiu Huo; Qianyu Guo; Junping Hu; Na Li; Rui Gao; Liangyu Mi; Zhaoliang Zhang; Hechao Liu; Zhiying Guo; Hanxi Zhao; Liyun Zhang; Ke Xu
Journal:  Drug Des Devel Ther       Date:  2022-04-02       Impact factor: 4.162

6.  Pirfenidone inhibits cell fibrosis in connective tissue disease-associated interstitial lung disease by targeting the TNF-α/STAT3/KL6 pathway.

Authors:  Yanhua Zuo; Jing Liu; Huaheng Xu; Yanxia Li; Ran Tao; Zongfang Zhang
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

Review 7.  Gain-of-function defects in toll-like receptor 8 shed light on the interface between immune system and bone marrow failure disorders.

Authors:  Jack Bleesing
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

Review 8.  Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype.

Authors:  Laura Faletti; Stephan Ehl; Maximilian Heeg
Journal:  Biomed J       Date:  2021-03-20       Impact factor: 4.910
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.